Steven Axon

Steven Axon has more than 20 years of corporate development and leadership experience in pharma and biotech. Prior to Glycomine, Mr. Axon served as CEO of Prothelia, a preclinical company focused on the development of a protein replacement therapy for patients with congenital muscular dystrophy. Prior to Prothelia, Mr. Axon served as Chief Business Officer of Apellis Pharmaceuticals, a global biopharmaceutical company that develops treatments focused on disorders of the innate immune system. Prior to joining Apellis, Mr. Axon worked at Serono and Merck KGaA in Switzerland and the US with progressive leadership roles in Corporate Strategy, Alliance Management and Business Development. Most recently, he served as Senior Vice President, Business Development. During his 12 year tenure at Merck, Mr. Axon led more than 50 transactions across all therapeutic areas and stages of development. He received a B.Sc and M.Sc. in biomechanical and biomedical engineering from the University of Toronto and his MBA from the International Institute for Management Development in Lausanne, Switzerland.